111's (YI) "Sell (E+)" Rating Reiterated at Weiss Ratings

111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating restated by research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

111 Stock Up 1.6%

Shares of 111 stock traded up $0.13 on Friday, hitting $7.74. The company's stock had a trading volume of 4,338 shares, compared to its average volume of 23,500. The company has a market capitalization of $66.15 million, a P/E ratio of -1.93 and a beta of 0.47. The firm has a fifty day moving average price of $8.22 and a 200-day moving average price of $7.40. 111 has a 52-week low of $4.15 and a 52-week high of $14.10.

111 (NASDAQ:YI - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $527.14 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in YI. Deuterium Capital Management LLC purchased a new position in 111 in the 1st quarter valued at about $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 111 during the 1st quarter valued at about $92,000. JPMorgan Chase & Co. increased its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 during the 4th quarter valued at about $245,000. Finally, FIL Ltd acquired a new position in shares of 111 during the 4th quarter valued at about $450,000. 21.32% of the stock is currently owned by hedge funds and other institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.